首页> 美国卫生研究院文献>Acta Crystallographica Section F: Structural Biology and Crystallization Communications >Expression purification and preliminary X-ray crystallographic studies of the human immunodeficiency virus 1 subtype C protease
【2h】

Expression purification and preliminary X-ray crystallographic studies of the human immunodeficiency virus 1 subtype C protease

机译:人免疫缺陷病毒1 C型蛋白酶的表达纯化及X射线晶体学初步研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Crystals of the human immunodeficiency virus 1 (HIV-1) subtype C protease (PR) complexed with the clinically used inhibitors indinavir (IDV) and nelfinavir (NFV) have been grown in the monoclinic space group P21, with mean unit-cell parameters a = 46.7 (±0.1), b = 59.8 (±0.3), c = 87.0 (±0.4) Å, β = 95.2 (±0.5)°. The crystals of both complexes have been shown to diffract X-rays to 2.3 Å resolution. The diffraction data for the subtype C PR complexes with IDV and NFV were subsequently processed and reduced, with overall R sym values of 8.4 and 11.4%, respectively. Based on the unit-cell volumes, molecular-replacement results and packing considerations, there are two protease homodimers per crystallographic asymmetric unit in each of the complexes. The data were initially phased using a model based on the crystal structure of HIV-1 subtype B PR; the structures have been determined and further refinement and analysis are in progress. These structures and subsequent studies with other inhibitors will greatly aid in correlating the amino-acid variation between the different HIV PRs and understanding their differential sensitivity and resistance to current drug therapy.
机译:与临床使用的抑制剂茚地那韦(IDV)和奈非那韦(NFV)复合的人类免疫缺陷病毒1(HIV-1)C型蛋白酶(PR)的晶体已在单斜空间群P21中生长,其平均单位细胞参数为= 46.7(±0.1)°,b = 59.8(±0.3)°,c = 87.0(±0.4)Å,β= 95.2(±0.5)°。两种配合物的晶体都显示出将X射线衍射到2.3Å分辨率。随后处理并减少了IDV和NFV的C PR亚型复合物的衍射数据,总R sym值分别为8.4和11.4%。基于单位细胞体积,分子置换结果和包装考虑,每种配合物中每个晶体学不对称单元都有两个蛋白酶同二聚体。最初使用基于HIV-1 B型亚型PR晶体结构的模型对数据进行分阶段;已经确定了结构,并且正在进一步完善和分析。这些结构以及随后与其他抑制剂的研究将大大有助于关联不同HIV PRs之间的氨基酸变异,并了解它们对当前药物治疗的不同敏感性和耐药性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号